FRANCE – PulseSight Therapeutics, a Paris, France-based ophthalmology biotech company, raised an undisclosed amount in Seed funding.
The round was led by Pureos Bioventures and ND Capital, with participation from Korea Investment Partners.The company intends to use the funds to expand operations and its R&D sector.Led by CEO Judith Greciet, PulseSight Therapeutics is an ophthalmology drug development company developing non-viral gene therapies with minimally-invasive delivery technology designed to address the unmet need for treatments against severe retinal diseases leading to blindness, with a focus on age-related macular degeneration (AMD) including wet AMD and geographic atrophy (GA) in late-stage dry AMD.Lead program, PST-809, in wet AMD and a second program, PST-611, in dry AMD/GA are at the very late stage of preclinical IND enabling studies and build on over a decade of development of non-viral gene therapies. Already validated in the clinic for safety and delivery, this non-viral delivery platform delivers DNA plasmids encoding therapeutic proteins into the ciliary muscle to safely and sustainably treat major eye diseases. The company’s technology and therapeutic applications are covered by an IP portfolio of 11 patent families, with 90 granted patents.Commenting on the news, Judith Greciet said: “I am excited to join the company with a validated and highly differentiating delivery platform and two non-viral gene therapy programs at late preclinical stage. Our proprietary non-viral gene therapy approach provides unique features in terms of efficacy, safety and durability of effect and I am thrilled to have the opportunity to work with PulseSight Therapeutics’ highly experienced team and board to build the company’s future.”28/02/2024
